BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 1:47:00 PM | Browse: 1194 | Download: 1202
 |
Received |
|
2013-05-09 09:05 |
 |
Peer-Review Started |
|
2013-05-09 21:43 |
 |
To Make the First Decision |
|
2013-05-23 17:11 |
 |
Return for Revision |
|
2013-06-07 10:24 |
 |
Revised |
|
|
 |
Second Decision |
|
2013-10-16 09:11 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-10-16 10:29 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-12-19 18:58 |
 |
Publish the Manuscript Online |
|
2014-01-16 17:21 |
Category |
Neurosciences |
Manuscript Type |
Frontier |
Article Title |
Cannabinoids: Do they have the potential to treat the symptoms of multiple sclerosis?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Zubair Ahmed |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
University of Birmingham |
|
|
Corresponding Author |
Dr. Zubair Ahmed, Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Institute of Biomedical Research (West), Edgbaston, Birmingham B15 2TT, United Kingdom. z.ahmed.1@bham.ac.uk |
Key Words |
Multiple sclerosis; Axonal damage; Neurodegeneration; Neuroprotection |
Core Tip |
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system and causes disability, neuropathic pain, spasticity and tremor in affected patients. Although illegal, users of cannabis report relief from pain and spasticity, probably due to the endogenous cannabinoid system that exists. cannabinoid receptor type-1 (CB1)-deficient mice accrue greater levels of neurodegeneration and poorly tolerate inflammatory and excitotoxic insults after immune attack in a model of MS, experimental allergic encephalomyelitis. Treatment of animals affected by experimental allergic uveitis (EAU) with CB1 agonists also provided significant neuroprotection from the consequences of EAU, suggesting that cannabinoids may slow down neurodegeneration in MS. |
Publish Date |
2014-01-16 17:21 |
Citation |
Ahmed Z. Cannabinoids: Do they have the potential to treat the symptoms of multiple sclerosis? World J Neurol 2013; 3(4): 87-96 |
URL |
http://www.wjgnet.com/2218-6212/full/v3/i4/87.htm |
DOI |
http://dx.doi.org/10.5316/wjn.v3.i4.87 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345